Bharat Biotech Commits 500 Million Doses Of Covaxin To Centre

Bharat Biotech's Covaxin demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the B.1.617.2 Delta variant, Bharat Biotech said recently, while announcing the final analysis of the jab. It had said the Efficacy Analysis demonstrates Covaxinto be 93.4%

Bharat Biotech Commits 500 Million Doses Of Covaxin To Centre

Bharat Biotech said it has committed to supply over 500 million doses of Covaxin to the Centre

Hyderabad:

Bharat Biotech today said it has committed to supply over 500 million doses of its COVID-19 vaccine Covaxin to the Centre under the countrywide immunisation programme.

Speaking at a virtual conference organised by the Confederation of Indian Industry, Suchitra Ella, joint Managing Director of the city-based vaccine maker, said the companys facilities in four cities - Hyderabad, Bengaluru, Pune and Ankaleshwar - are currently producing Covaxin.

"In a nutshell if I have to tell you, this is the journey of Covaxin from April 2020 until June 2021. And it is still ongoing as we continue to manufacture, taking a commitment of more than 50 crore (500 million) of doses to be submitted to the government of India for its immunisation programme," she said narrating the journey of Covaxin.

Minister of State for Health Bharati Pravin Pawar had said in Parliament on Tuesday that from January to July 16, 5.45 crore (54.5 million) doses of Covaxin by Bharat Biotech and 36.01 (360 million) crore doses of Covishield have been supplied by the Serum Institute of India to the Centre.

Suchitra Ella said the data of Phase 3 trials has been submitted to the Drug Controller General of India for its perusal and efficacy of the vaccine against many of the coronavirus variants was also tested.

Covaxin demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the B.1.617.2 Delta variant, Bharat Biotech said recently, while announcing the final analysis of the jab.

It had said the Efficacy Analysis demonstrates Covaxinto be 93.4 per cent effective against severe symptomatic COVID-19 cases.

The Managing Director further said that when it comes to vaccines not only for COVID-19, India, when compared to some other countries, has more capacity to produce vaccines in large numbers.
 

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)